Mark Brönstrup studied Chemistry at the Philipps-Universität Marburg and at the Imperial College in London. He received his doctorate from the Technical University Berlin in Organic Chemistry. He worked from 2000 to 2013 for Aventis, Sanofi-Aventis and Sanofi, complemented by a research sabbatical in 2003 at Harvard Medical School. He led the Natural Product Sciences section with the goal of discovering leads from natural sources and optimising them to clinical candidates, and he dealt with translational research projects as a domain head for Biomarkers, Bioimaging & Biological Assays. Since December 2013, he heads the department Chemical Biology at the Helmholtz Centre for Infection Research (HZI). Additionally, he holds a Professorship (W3) at the Leibniz Universität Hannover. He is also the cooordinator of the cross-topic ‘drug research’ within the Helmholtz association and the speaker of the topic ‘novel antiinfectives’ of the HZI. His research is focused on the discovery, characterization and optimization of novel antibacterial and antiviral drugs.